Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Scrip AMR Round Table Part 4: Pipeline Progress But Education Needs Work

Executive Summary

In a round table discussion held on the sidelines of the ECCMID conference in Amsterdam in April 2016, a panel of experts offered their perspectives on the problem of antimicrobial resistance, and what it will take to protect the world's population from this threat.

In Part 4, the panelists speak about the R&D pipeline and about the challenges of educating doctors and patients on antibiotic stewardship.

The round table was chaired by Scrip Editor Eleanor Malone, and the panelists were:

  • John Rex, Senior Vice-President and Chief Strategy Officer for AstraZeneca's antibiotics business unit.
  • Professor Mike Sharland, Professor of Paediatric Infectious Disease at St George's University Hospital and Chair of a government Expert Advisory Committee on AMR for England.
  • Roman Kozlov, Chief Specialist at the Ministry of Health of the Russian Federation in Clinical Microbiology and Antimicrobial Resistance, and a Director at the Institute of Antimicrobial Chemotherapy at the Smolensk State Medical University.
  • Matteo Bassetti, head of Infectious Diseases Division of the Santa Maria Misericordia University Hospital in Udine, Italy, and Professor of Infectious Diseases at the School of Medicine and Postgraduate School of Infectious Diseases at the University of Udine.

This Round Table was hosted by Scrip with sponsorship from AstraZeneca.


Related Content

Expert Round Table: Can We Beat AMR?
Scrip AMR Round Table Part 1: Green Shoots After Long Winter
Scrip AMR Round Table Part 2: We Need More Numbers
Jim O'Neill Optimistic His AMR Review Won't Run Into The Sand
BIO 2015 Dispatches: Antibiotics: Uninteresting to investors, tough to find advocates
New antibiotic discovery network fills hole but needs cash





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts